The annual general meeting of shareholders for 2025 of Vietnam Pharmaceutical Corporation (Vinapharm) aimed to boost pre-tax profit into double digits, despite challenges in the pharmaceutical distribution sector seeing slower growth. Forecasts project revenue of 327 billion VND in 2025, a 4% increase, and a pre-tax profit of 273 billion VND, an 11% rise compared to 2024. Vinapharm is focusing on increasing its ownership in Sanofi Vietnam from 15% to 30% to capitalize on profits from this partner. The company is also planning to collaborate with South Korea’s Celltrion in the biopharmaceutical sector and expand relationships with international partners. The general assembly approved a 10% dividend payout for 2024 and emphasized the importance of developing human resources and reforming corporate governance to enhance operational efficiency.
Leave a Reply